Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Neurocrine Biosciences

NBIX Healthcare Unknown Updated July 20, 2026
$178.88
52W $122.14 – $181.18
65/100
25.8
0.39
Explore NBIX Further
📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
AI Committee Verdict
Buy
Conviction: Contested · 57% agreement · 7 analysts
-22.8%
Contested
Is NBIX Bullish or Bearish?
Bullish. Innellis AI committee rates Neurocrine Biosciences (NBIX) Buy with a composite score of 65/100 , based on 7 analysts with 57% agreement. Last updated July 20, 2026.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
  • Daily trend: uptrend.
  • Weekly trend: uptrend.
  • Daily and weekly trends are both bullish — multi-timeframe alignment, highest confidence.
  • Higher Highs / Higher Lows structure confirms bullish price action.
  • Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
  • MACD histogram is negative (-0.862) — bearish momentum.
Price History (6M)
AI Investment Committee
Committee Consensus As of July 20, 2026
Overall Committee Score
65/100
Agreement
57%
Analysts
7
Conviction
Contested
Value Analyst neutral
54 / 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 21.6% shows genuine earnings power backing the valuation
− P/E of 26.0 is moderate-to-rich
Growth Analyst bullish
85 / 100 · High confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 28.6% YoY -- genuine top-line momentum
Technical Analyst neutral
57 / 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst bullish
75 / 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
70 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.40 across 26 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2975.52)
Open Full Terminal →
Investment Thesis Evolution

Committee score moved marginally from 65.2 to 65.2.

Analyst-level changes:
  • News Analyst: +1 bullish signal(s).
  • Portfolio Manager: +1 bearish signal(s).
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-07-19 to 2026-07-20 (1 day apart).

Technical Analysis
RSI (14)
54.1
Neutral
MACD Histogram
-0.862
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.59
Inside Bands
Price vs Moving Averages
EMA 9
$172.70 Above
EMA 21
$170.34 Above
EMA 50
$162.44 Above
EMA 200
$145.95 Above
Fundamental Analysis
Valuation
67
Growth
72
Profitability
1
Financial Health
100
Cash Flow
37
Valuation
P/E Ratio 25.8×
P/B Ratio 5.10×
PEG Ratio 0.21
Dividend Yield 0.00%
52W High $181.18
52W Low $122.14
Quality & Growth
ROE 14.7%
ROA 10.3%
Gross Margin 98.2%
Operating Margin 25.2%
Revenue Growth YoY
Debt / Equity 0.12
AI Fundamental Assessment
P/E ratio of 25.8 (moderate relative to a 15-40x range); Price-to-book of 5.1x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.1%; Return on assets of 0.1%; Net margin of 0.2%; Gross margin of 1.0%; Current ratio of 2.93 (healthy short-term liquidity); Debt-to-equity of 0.12; Free cash flow margin of 1.0% (thin cash generation); Free cash flow per share is positive (8.27); Most recent quarter beat estimates by 62.3%; EPS growth accelerating (-27.5% -> +29.1% QoQ); Analyst estimates falling over recent quarters
Key Risks
  • MACD histogram is negative (-0.862) — bearish momentum.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full NBIX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal → Mobile
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime